ATE346083T1 - Dem fibroblasten wachstumsfaktor homologer faktor-1(fhf-1) und methoden zu seiner verwendung - Google Patents

Dem fibroblasten wachstumsfaktor homologer faktor-1(fhf-1) und methoden zu seiner verwendung

Info

Publication number
ATE346083T1
ATE346083T1 AT96915685T AT96915685T ATE346083T1 AT E346083 T1 ATE346083 T1 AT E346083T1 AT 96915685 T AT96915685 T AT 96915685T AT 96915685 T AT96915685 T AT 96915685T AT E346083 T1 ATE346083 T1 AT E346083T1
Authority
AT
Austria
Prior art keywords
fhf
factor
fibroblast growth
methods
growth factor
Prior art date
Application number
AT96915685T
Other languages
English (en)
Inventor
Jeremy Nathans
Philip M Smallwood
Jennifer P Macke
Original Assignee
Univ Johns Hopkins Med
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Johns Hopkins Med filed Critical Univ Johns Hopkins Med
Application granted granted Critical
Publication of ATE346083T1 publication Critical patent/ATE346083T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/50—Fibroblast growth factor [FGF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Toxicology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Neurosurgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AT96915685T 1995-05-12 1996-05-10 Dem fibroblasten wachstumsfaktor homologer faktor-1(fhf-1) und methoden zu seiner verwendung ATE346083T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/439,725 US5693775A (en) 1995-05-12 1995-05-12 Fibroblast growth factor homologous factor-1 (FHF-1) and methods of use

Publications (1)

Publication Number Publication Date
ATE346083T1 true ATE346083T1 (de) 2006-12-15

Family

ID=23745874

Family Applications (1)

Application Number Title Priority Date Filing Date
AT96915685T ATE346083T1 (de) 1995-05-12 1996-05-10 Dem fibroblasten wachstumsfaktor homologer faktor-1(fhf-1) und methoden zu seiner verwendung

Country Status (8)

Country Link
US (4) US5693775A (de)
EP (2) EP1626096A3 (de)
JP (1) JPH11508125A (de)
AT (1) ATE346083T1 (de)
AU (1) AU718718B2 (de)
CA (1) CA2220893A1 (de)
DE (1) DE69636720T2 (de)
WO (1) WO1996035708A1 (de)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050019824A1 (en) * 1994-03-08 2005-01-27 Human Genome Sciences, Inc. Fibroblast Growth Factor-10
US6110893A (en) * 1995-06-05 2000-08-29 Human Genome Sciences, Inc. Fibroblast growth factor 11
US6605441B1 (en) 1995-06-05 2003-08-12 Human Genome Sciences, Inc. Antibodies against fibroblast growth factor 11
CA2217301A1 (en) * 1995-06-05 1996-12-12 Human Genome Sciences, Inc. Fibroblast growth factor 15
JPH11507502A (ja) * 1995-06-05 1999-07-06 ヒューマン・ジェノム・サイエンシズ・インコーポレイテッド ヒトクリプチン増殖因子
US5773252A (en) 1995-06-05 1998-06-30 Human Genome Sciences, Inc. Fibroblast growth factor 15
US6020189A (en) 1996-08-30 2000-02-01 The Johns Hopkins University School Of Medicine Fibroblast growth factor homologous factors (FHFs) and methods of use
EP0942981A1 (de) * 1996-11-27 1999-09-22 Human Genome Sciences, Inc. Fibroblasten-wachstumsfaktor 13
US6331523B1 (en) 1998-03-12 2001-12-18 Genentech, Inc. Method of enhancing the survival of retinal neurons and treating ocular diseases using FGF-5
US7022683B1 (en) 1998-05-13 2006-04-04 Carrington Laboratories, Inc. Pharmacological compositions comprising pectins having high molecular weights and low degrees of methoxylation
US5929051A (en) * 1998-05-13 1999-07-27 Carrington Laboratories, Inc. Aloe pectins
US6313103B1 (en) 1998-05-13 2001-11-06 Carrington Laboratories, Inc. Pectic substance as a growth factor stabilizer
US20030166550A1 (en) 1999-08-27 2003-09-04 Chiron Corporation Angiogenically effective unit dose of FGF-2 and method of use
US7018810B1 (en) * 1999-12-07 2006-03-28 Amgen Inc. Chordin-like molecules and uses thereof
US20060160181A1 (en) * 2000-02-15 2006-07-20 Amgen Inc. Fibroblast Growth Factor-23 molecules and uses thereof
JP2004504063A (ja) * 2000-07-19 2004-02-12 アドバンスド　リサーチ　＆　テクノロジー　インスティテュート 新規線維芽細胞増殖因子（ｆｇｆ２３）および使用方法
US7494669B2 (en) 2001-02-28 2009-02-24 Carrington Laboratories, Inc. Delivery of physiological agents with in-situ gels comprising anionic polysaccharides
US7595296B1 (en) * 2006-11-09 2009-09-29 Florida State University Research Foundation, Inc. Mutant polypeptides of fibroblast growth factor 1
US7659379B1 (en) * 2007-05-24 2010-02-09 Florida State University Research Foundation, Inc. Mutants of human fibroblast growth factor having increased stability and/or mitogenic potency
EP2357020B1 (de) * 2010-02-17 2012-08-29 Sorin CRM SAS Aktive medizinische Vorrichtung vom Typ Herzschrittmacher, Defibrillator und/oder Resynchronisator mit automatischer Optimierung der atrioventrikulären Verzögerung
AU2011239386B2 (en) 2010-04-16 2015-03-19 Salk Institute For Biological Studies Methods for treating metabolic disorders using FGF
WO2015061351A1 (en) * 2013-10-21 2015-04-30 Salk Institute For Biological Studies Chimeric fibroblast growth factor (fgf) 2/fgf1 peptides and methods of use
KR101868620B1 (ko) * 2015-08-12 2018-07-23 중앙대학교 산학협력단 Fgf12를 이용한 혈관 평활근세포 증식성 질환의 진단, 예방 또는 치료용 조성물
JP2018535964A (ja) 2015-10-30 2018-12-06 ソーク インスティテュート フォー バイオロジカル スタディーズ 線維芽細胞増殖因子（ｆｇｆ）１アナログによるステロイド誘導性高血糖の処置
US11542309B2 (en) 2019-07-31 2023-01-03 Salk Institute For Biological Studies Fibroblast growth factor 1 (FGF1) mutant proteins that selectively activate FGFR1B to reduce blood glucose

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69425890D1 (de) * 1993-06-04 2000-10-19 Us Health Verfahren zur behandlung von kaposi-sarcoma mit antisense-oligonukleotide
US5817485A (en) * 1994-03-08 1998-10-06 Human Genome Sciences, Inc. Nucleic acids and cells for recombinant production of fibroblast growth factor-10
US5763214A (en) * 1995-06-05 1998-06-09 Human Genome Sciences, Inc. Fibroblast growth factor 11
CA2217301A1 (en) * 1995-06-05 1996-12-12 Human Genome Sciences, Inc. Fibroblast growth factor 15
CA2249179A1 (en) * 1996-03-21 1997-09-25 The Johns Hopkins University School Of Medicine Fibroblast growth factor homologous factor-3 (fhf-3) and methods of use
US6020189A (en) * 1996-08-30 2000-02-01 The Johns Hopkins University School Of Medicine Fibroblast growth factor homologous factors (FHFs) and methods of use

Also Published As

Publication number Publication date
JPH11508125A (ja) 1999-07-21
US20030220483A1 (en) 2003-11-27
DE69636720T2 (de) 2007-10-18
US5693775A (en) 1997-12-02
AU5739796A (en) 1996-11-29
EP1626096A2 (de) 2006-02-15
US5872226A (en) 1999-02-16
EP0825996A1 (de) 1998-03-04
DE69636720D1 (de) 2007-01-04
EP1626096A3 (de) 2007-04-11
EP0825996B1 (de) 2006-11-22
EP0825996A4 (de) 2000-06-14
CA2220893A1 (en) 1996-11-14
US20020052477A1 (en) 2002-05-02
WO1996035708A1 (en) 1996-11-14
AU718718B2 (en) 2000-04-20

Similar Documents

Publication Publication Date Title
ATE346083T1 (de) Dem fibroblasten wachstumsfaktor homologer faktor-1(fhf-1) und methoden zu seiner verwendung
ATE295414T1 (de) Menschliche ctla-8 und verwendung von ctla-8 ähnlichen proteinen
IS4884A (is) Ret bindill til örvunar vaxtar tauga og thvagfæra
NO960767D0 (no) Protocadherinproteiner og deres anvendelse
DE68929043D1 (de) Für androgen-rezeptor-protein kodierende dna
ATE263836T1 (de) Chimere proteine, welche borrelia polypeptide beinhalten, verwendungen dafür
DK0572688T3 (da) Peptider, med organ-beskyttende aktivitet, fremgangsmåde til deres fremstilling og deres anvendelse ved terapi
EE05497B1 (et) Polüpeptiid, lahustuv CRAM-1 polüpeptiid, polünukleotiid ja antikeha
ATE235916T1 (de) Verfahren zur herstellung von gegen e.coli bakterien der familie cs4-cfa/1 gerichteten antikörpern
DE69937269D1 (de) Bioaktive Peptide, ihre Verwendung und Verfahren zu ihre Herstellung
DE69334146D1 (de) Peptide mit gdp-austauschfaktorartiger wirkung, dafür kodierende nukleinsäuresequenzen, ihre herstellung und verwendung
EP0967283A4 (de) Gene, die für proteine mit transglykolysierungsaktivität kodieren.
ATE432287T1 (de) Peptidfragmente mit den zelltod verhindernder aktivität
DE3854420D1 (de) Onkogen kodierendes polypeptid, das wachstumsfaktoraktivität besitzt, verfahren zu seiner herstellung und verwendung.
EP0816504A3 (de) Acetylhydrolase des Plättchen aktivierenden Faktors, und entsprechendes Gen
EP0832109A4 (de) Faktor-2, homolog zum fibroblasten-wachstumsfaktor und verfahren zu seiner anwendung
NO975565L (no) Benstimulerende faktor
DE69831141D1 (de) Z2-19a, ein menschliches homolog von dem protein 2-19
DK0941341T3 (da) Nukleotidsekvens, der koder for en flavinmonooxygenase, det tilsvarende protein og deres anvendelser inden for diagnostik og terapi
DK595187A (da) Minactivin og fremgangsmaade til fremstilling deraf
DE59109235D1 (de) Peptide des HIV-gag Proteins, ihre Herstellung und Verwendung
DK0555785T3 (da) Glat-muskel-mitogent stof og DNA, der koder herfor
FI901764A7 (fi) Synteettinen DNA-sekvenssi, joka koodaa ihmisen insuliinin kaltaista k asvutekijää II
DE59813388D1 (de) Polypeptide mit Aminosäuresequenzen aus dem N-terminalen Bereich von gp116 von Cytomegalovirus und deren Verwendung bei der Diagnostik, Prophylaxe und Therapie
ATE432985T1 (de) Polypeptide mit aktivität der stimulierung von neutrophilen

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties